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Abstract
To evaluate the onset timing of musculoskeletal adverse events (MAEs) that develop
during statin monotherapy and to determine whether concomitant drugs used con-
currently with statin therapy shifts the onset timing of MAEs. Cases in which statins
(atorvastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin, and
pravastatin) were prescribed were extracted from the US Food and Drug Adminis-
tration (FDA) Adverse Event Reporting System (FAERS) Data Files. The onset timing
of MAEs during statin monotherapy was evaluated by determining the difference
between statin start date and MAE onset date. The use of concomitant drugs with
statin therapy was included in the analysis. Statins used in combination with con-
comitant drugs were compared with statin monotherapy to determine if the use of
concomitant drugs shifted the onset timing of MAEs. The onset of MAEs was signif-
icantly faster with atorvastatin and rosuvastatin than with simvastatin. A difference
in onset timing was not detected with other statins because the number of cases
was too small for analysis. When evaluating concomitant drug use, the concomitant
drugs that shifted the onset timing of MAEs could not be detected. Statins with
strong low‐density lipoprotein cholesterol‐lowering effects (atorvastatin and rosuvas-
tatin) contributed not only to a high risk of MAE onset, but also to a shorter time‐
to‐onset. No concomitant drug significantly shifted the onset timing of MAEs when
used concurrently with statins.
K E YWORD S
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1 | INTRODUCTION
Statins are 3‐hydroxy 3‐methylglutaryl CoA (HMG‐CoA) reductase
inhibitors and low‐density lipoprotein (LDL) cholesterol‐lowering
agents. They are well‐tolerated and are known to lower the risk
Abbreviations: FAERS, Food and Adverse Event Reporting System; FDA, Food and Drug
Administration; HMG-CoA, 3-hydroxy 3-methylglutaryl CoA; LDL, low-density lipoprotein;
MAEs, musculoskeletal adverse events.
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of atherosclerotic cardiovascular disease (ASCVD).1,2 However, if
musculoskeletal adverse events (MAEs) such as myalgia, myopathy,
and rhabdomyolysis develop during the statin use period, these
cholesterol‐lowering treatments may need to be temporarily or
permanently discontinued.2 There are a few reports detailing the
onset timing of drug‐induced adverse events.3,4 In 2004, Chang et
al reported the onset timing of statin‐induced rhabdomyolysis.5
However, the difference in onset timing of rhabdomyolysis
between each statin was not detected owing to few number of
cases.
It is difficult to detect drug‐drug interactions (DDIs) that may
cause severe adverse events at the stage of drug approval exami-
nation.6 DDIs are usually discovered during postmarketing surveil-
lance.7,8 It is already known that the concomitant use of statins
and specific nonstatin drugs increases the risk of rhabdomyolysis.
For example, the concomitant use of statins with fibrates9-11 or
cytochrome P450 (CYP) inhibitors, such as clarithromycin (CYP3A4
inhibitor), cyclosporine (CYP3A4 inhibitor), and clopidogrel (CYP2C8
inhibitor), increases the risk of rhabdomyolysis.12-14 It has been
reported that the increased risk of statin‐induced rhabdomyolysis
may be due to the pharmacokinetic changes caused by concomi-
tant drugs.15 If DDIs cause changes in the time‐course of blood
concentration of statins, it not only changes the onset risk, but
may also affect the onset timing. There are limited studies evaluat-
ing the risk of concomitant drugs on the onset timing of statin
adverse events.
To reduce and prevent the risk of adverse events in a clinical
setting, it is important to acquire information on both the risk and
onset timing of drug‐induced adverse events. We have already eval-
uated the onset timing of adverse events as well as the risk of these
events.3,16 Although many drugs have the potential to cause the
same adverse event, especially those within the same medication
class, the onset timing of these events for individual drugs may dif-
fer; thus, it is important to evaluate the onset timing of side effects
associated with each drug.
The Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS) is often used to detect DDIs. Risk evalu-
ation using disproportionality is performed to determine these
DDIs.17,18 Although the incidence of statin‐induced MAEs differs in
literature, statins are well‐tolerated and rarely cause MAEs. There-
fore, the incidence of statin‐induced MAEs is very low,11,19,20 and
it is difficult to evaluate the onset timing of statin‐induced MAEs
through clinical trials as these adverse events may occur within
12 months of starting statin therapy or after many years.10 Since
clinical trials are performed only for a specific period, postmarket-
ing surveillance and reporting of adverse events through FAERS is
helpful to determine the onset timing of MAEs. The FAERS is a
large‐scale database that accumulates reported cases of adverse
events; thus, it is suitable for analysing MAEs that develop at a
low frequency during statin use.
Therefore, this study was aimed at investigating the onset timing
of MAEs in cases using statin monotherapy and if concomitant drugs
shifted the onset timing of MAEs.
2 | MATERIALS AND METHODS
2.1 | Data sources
The FAERS database Quarterly Data Files (Q1 2004 to Q3 2017)
published by the FDA (downloaded in February 2018) was used to
evaluate the adverse events associated with statin therapy. The
Quarterly Data Files comprise 7 types of datasets (patient demo-
graphic and administrative information, DEMO; drug/biologic infor-
mation, DRUG; adverse events, REAC; patient outcomes, OUTC;
report sources, RPSR; drug therapy start and end dates, THER; and
indication for use/diagnosis, INDI). Of these, DEMO, DRUG, REAC,
and THER files were used for analyses.
2.2 | Definition of MAEs
The following events were considered as MAEs based on a previous
report21 taken from the Medical Dictionary for Regulatory Activities
(MedDRA, version 20.1) at the Preferred Term level: “rhabdomyolysis”
(MedDRA code 10039020), “myalgia” (10028411), “myoglobinuria”
(10028629), and “blood creatine phosphokinase increased” (10005470).
2.3 | Standardisation of names of drugs reported to
FAERS
The drugs reported to FAERS can be registered by arbitrary names,
including trade names and typographical errors.22 Therefore, we
used DRUGBANK (version 5.0.11) to standardise the names of
drugs, including statins and other concomitant drugs.23
2.4 | Data extraction
Figure 1 contains a flowchart depicting the study procedure from
the extraction of cases reported in the FAERS to the calculation of
MAE onset timing.
From the FAERS Quarterly Data Files, only cases in which ator-
vastatin, rosuvastatin, simvastatin, lovastatin, fluvastatin, pitavastatin,
and pravastatin were prescribed were extracted for analysis. These
selected cases were then condensed to cases in which the start date
of statin use had been accurately recorded. Condensed cases with
the recorded use of two or more statins were excluded, and the
remaining cases were categorised as statin+ cases. Only cases who
received a statin and experienced MAEs (ie MAE+/statin+ cases)
were extracted. Among MAE+/statin+ cases, those cases in which
MAEs developed after statin discontinuation or cases in which MAEs
developed before the start of statin use were excluded. Finally, the
MAE+/statin+ cases were divided into cases of statin monotherapy
and cases of concomitant use of a specific statin and other drugs.
2.5 | Cases of statin monotherapy
Some of the cases reported to the FAERS were the same cases that
were reported by different reporters (duplicate cases). Thus, to exclude
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duplicate cases from our analysis, among the cases of statin monother-
apy reported, cases in which all the 4 items of age, sex, adverse event
onset date (EVENT_DT), and start date of statin use (START_DT), were
the same were regarded as duplicate cases and eliminated. The differ-
ences between EVENT_DT and START_DT of cases of statin
monotherapy were regarding the time‐to‐onset for MAEs. As the onset
period (time‐to‐onset) of MAEs during statin use was mostly within
1 year,10 cases of statin monotherapy in which MAEs had developed
within 365 days were selected for analysis in this study. A statistical
analysis was performed to determine whether the time‐to‐onset of
MAEs differed with statin type. In addition, statins for which less than
30 cases were reported for analysis were not included in the subse-
quent study in which the impact of concomitant drugs on the time‐to‐
onset of MAEs was investigated (described below).
2.6 | Cases of concomitant use of a specific statin
and other drugs
“Concomitant use of a specific statin and other drugs” here is
defined as the concurrent administration of a specific statin and
at least one type of nonstatin drug. The nonstatin drug(s) would
need to be taken during the use period of the specific statin to
investigate whether they can shift the onset timing of statin‐
induced MAEs. If the statin use period and the use period of
specified concomitant drugs (nonstatin) overlap, the risk of drug
interactions may increase. Therefore, in cases of concomitant use
of a specific statin and other drugs, nonstatin concomitant drugs
used concurrently during statin use were selected for analysis (Fig-
ure 2A and B), while concomitant drugs that had been discontin-
ued before the start date of statin use (START_DT) were excluded
from the analysis (Figure 2C).
Among the reported cases of concomitant use, cases in which all
the 4 items of age, sex, adverse event onset date (EVENT_DT), and
the start date of statin use (START_DT) were the same were
regarded as duplicate cases and thus deleted.
The differences between EVENT_DT and START_DT of the cases
of concomitant use of a specific statin and other drugs were regard-
ing the time‐to‐onset for MAEs, and these cases in which MAEs had
developed within 365 days were selected for analysis. This proce-
dure is the same as “Cases of statin monotherapy”. A statistical anal-
ysis was performed for concomitant drugs with more than 30 cases
to determine whether the concomitant drugs changed the time‐to‐
onset of MAEs.
2.7 | Statistical analysis
Cases of statin monotherapy were collected and a nonparametric
method, the Steel‐Dwass test, was used to determine if the time‐to‐
onset of MAEs differed by statin type. This nonparametric analysis
method was adopted as it was assumed that the time‐to‐onset
would not be normally distributed. To determine if concomitant
drugs affected the time‐to‐onset of statin‐induced MAEs, paired
comparisons between cases of each concomitant drug use and cases
of statin monotherapy were also performed using the Steel test.
All statistical analyses were performed using R software (version
3.2.2, R Foundation for Statistical Computing, Vienna, Austria) for
Windows®. The significance level (P) was set at 0.05.
3 | RESULTS
3.1 | Time‐to‐onset of MAEs in cases of statin
monotherapy
Table 1 shows the number of cases of statin monotherapy and
the time‐to‐onset of MAEs. Among cases of atorvastatin
monotherapy, 454 cases for which the time‐to‐onset could be
Extracted cases reportedly taking designated statins from the FAERS Quarterly Data Files (Q1 
2004 to Q3 2017)
Selected cases with reported MAEs from the extracted cases
Excluded cases with concurrent use of 2+ statin drugs from selection
(Remaining cases designated as “MAE+ /statin+”a)
Excluded MAE+ /statin+ cases without MAE onset during the statin use period
Cases of statin monotherapy
Cases of concomitant use of 
statins and other drugs
Statin monotherapy
Concomitant use of 
statins and other drugs
De-duplication Extracted concomitant non-statin 
for analysis b
Calculated time-to-onset
for MAEs
De-duplication
Calculated time-to-onset
for MAEs
F IGURE 1 Flowchart for MAE time-to-
onset calculation. (a) I.e., cases who
received a statin drug and experienced
MAEs. (b) I.e., non-statin drugs whose use
period overlapped with that of the
designated statins. MAE, musculoskeletal
adverse event
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calculated were selected for analysis. Among the seven types of
statins, the number of cases of atorvastatin monotherapy was the
largest followed by rosuvastatin (413 cases), simvastatin (409
cases), pravastatin (82 cases), lovastatin (34 cases), fluvastatin (29
cases), and pitavastatin (16 cases) in this study. The minimum
time‐to‐onset for MAEs was 0.0 days (immediately after use)
regardless of the statin type. The statin with the shortest median
time‐to‐onset for MAEs was pitavastatin (14.0 days), followed by
atorvastatin (24.5 days), rosuvastatin (30.0 days), simvastatin
(38.0 days), pravastatin (43.0 days), fluvastatin (45.0 days), and
lovastatin (48.0 days).
The Steel‐Dwass test was performed to examine if the time‐to‐
onset of MAEs differed by statin type. The test showed that the
onset of MAEs induced by atorvastatin was significantly faster than
that of MAEs induced by simvastatin (P < 0.01, median: 24.5 days
vs 38.0 days). As in the case of atorvastatin, the onset of MAEs
induced by rosuvastatin was significantly faster than that of simvas-
tatin (P < 0.05, median: 30.0 days vs 38.0 days). However, the time‐
to‐onset of MAEs induced by atorvastatin and rosuvastatin was not
significant (P = 0.39, median: 24.5 days vs 30.0 days). The difference
in the time‐to‐onset of MAEs could not be detected for statins with
a small number of cases.
3.2 | Concomitant drug‐associated shift in the
onset timing of statin‐induced MAEs
Table 2 shows the time‐to‐onset of MAEs induced by atorvastatin
and concomitant drugs. Twenty‐four different individual drugs were
used concurrently with atorvastatin at a high frequency (≥30 cases),
and the most frequently used concomitant drug was aspirin (299
cases). Compared to atorvastatin monotherapy, the concomitant
drug that resulted in the shortest time‐to‐onset of MAEs was lisino-
pril (79 cases), with a median of 3.0 days and IQR of 0.0‐61.0 days.
In contrast, the concomitant drug that resulted in the longest time‐
to‐onset of MAEs was losartan (45 cases), with a median and IQR of
time‐to‐onset for MAEs of 74.0 days and 7.0‐125.0 days, respec-
tively. However, compared to atorvastatin monotherapy, these
24 concomitant drugs did not change the time‐to‐onset of MAEs
significantly.
Table 3 shows the time‐to‐onset of MAEs induced by rosuvas-
tatin and concomitant drugs. Twenty‐one concomitant drugs were
used concurrently with rosuvastatin at a high frequency, and the
most frequently used concomitant drug was aspirin (260 cases). The
concomitant drug that resulted in the shortest time‐to‐onset of
MAEs was ramipril (34 cases), with a median and IQR of time‐to‐
onset for MAEs of 12.0 and 0.0‐103.0 days, respectively. In contrast,
the concomitant drug that resulted in the longest time‐to‐onset of
MAEs was furosemide (65 cases), with a median and IQR of time‐to‐
onset for MAEs of 62.5 and 0.5‐144.0 days, respectively. Neverthe-
less, compared to rosuvastatin monotherapy, the 21 concomitant
drugs did not change the time‐to‐onset of MAEs significantly.
Table 4 shows the time‐to‐onset of MAEs induced by simvas-
tatin and concomitant drugs. Twenty‐six concomitant drugs were
used concurrently with simvastatin at a high frequency, and the
most frequently used concomitant drug was aspirin (249 cases).
The concomitant drug that resulted in the shortest time‐to‐onset
of MAEs was amlodipine (93 cases), with a median and IQR of
time‐to‐onset for MAEs of 12.5 and 0.0‐73.8 days, respectively. In
contrast, the concomitant drug that resulted in the longest time‐
to‐onset of MAEs was nitroglycerin (42 cases), with a median and
Use of specified concomitant drug
Statin use period (time-to-onset of MAEs)
MAE onset date
(EVENT_DT)
Day 0
(Start date of statin use, START_DT)
Use of specified concomitant drug
Statin use period (time-to-onset of MAEs)
MAE onset date
(EVENT_DT)
Day 0
(Start date of statin use, START_DT)
Discontinuation of concomitant drug
Use of specified concomitant drug
Statin use period (time-to-onset of MAEs)
MAE onset date
(EVENT_DT)
Day 0
(Start date of statin use, START_DT)
(Excluded from analysis)
Discontinuation of
concomitant drug
(A)
(B)
(C)
F IGURE 2 Selection of concomitant
drugs for analysis. MAE, musculoskeletal
adverse event
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IQR of time‐to‐onset for MAEs of 64.5 and 23.0‐197.3 days,
respectively. Nonetheless, compared to simvastatin monotherapy,
all these 26 concomitant drugs did not change the time‐to‐onset
of MAEs significantly.
Aspirin was the only concomitant drug used concurrently with
pravastatin at a high frequency (30 cases, median: 31.5 days; IQR:
4.0‐193.0 days), and compared to pravastatin monotherapy, its use
did not change the time‐to‐onset of MAEs significantly.
TABLE 1 Comparison of the onset timing of MAEs induced by each statin
Statin No. of cases
MAE onset (days)
IQRMinimum value First quartile Median Third quartile Maximum value
Atorvastatin† 454 0.0 0.0 24.5 78.8 361.0 0.0‐78.8
Rosuvastatin‡ 413 0.0 1.0 30.0 92.0 364.0 1.0‐92.0
Simvastatin†,‡ 409 0.0 7.0 38.0 122.0 363.0 7.0‐122.0
Pravastatin 82 0.0 7.3 43.0 113.0 330.0 7.3‐113.0
Lovastatin 34 0.0 0.0 48.0 70.0 325.0 0.0‐70.0
Fluvastatin 29 0.0 21.0 45.0 112.0 300.0 21.0‐112.0
Pitavastatin 16 0.0 0.0 14.0 68.3 258.0 0.0‐68.3
Steel‐Dwass test. IQR, interquartile range; MAEs, musculoskeletal adverse events.
†Compared with simvastatin, atorvastatin was associated with a significantly faster onset of MAEs (P < 0.01).
‡Compared with simvastatin, rosuvastatin was associated with a significantly faster onset of MAEs (P < 0.05).
TABLE 2 Onset timing of MAEs induced by atorvastatin and concomitant drugs
Concomitant drugs
No. of cases
(≥30 cases)
MAE onset (days)
IQRMinimum value First quartile Median Third quartile Maximum value
Lisinopril 79 0.0 0.0 3.0 61.0 276.0 0.0‐61.0
Valsartan 45 0.0 0.0 5.0 41.0 261.0 0.0‐41.0
Atenolol 76 0.0 0.0 5.5 67.5 326.0 0.0‐67.5
Metoprolol 116 0.0 0.0 7.5 62.0 359.0 0.0‐62.0
Levothyroxine 92 0.0 0.0 8.5 92.0 334.0 0.0‐92.0
Acetaminophen 63 0.0 0.0 9.0 60.0 297.0 0.0‐60.0
Hydrochlorothiazide 78 0.0 0.0 9.0 71.5 297.0 0.0‐71.5
Omeprazole 84 0.0 0.0 9.0 107.3 350.0 0.0‐107.3
Diltiazem 35 0.0 1.0 11.0 36.5 335.0 1.0‐36.5
Fluticasone 37 0.0 0.0 11.0 151.0 294.0 0.0‐151.0
Warfarin 34 0.0 0.3 12.5 144.5 334.0 0.3‐144.5
Metformin 67 0.0 0.0 13.0 92.0 294.0 0.0‐92.0
Pantoprazole 37 0.0 1.0 13.0 42.0 335.0 1.0‐42.0
Aspirin 299 0.0 0.0 18.0 93.0 359.0 0.0‐93.0
Furosemide 89 0.0 1.0 18.0 90.0 322.0 1.0‐90.0
Ramipril 56 0.0 0.0 21.0 96.0 319.0 0.0‐96.0
Clopidogrel 112 0.0 1.0 22.0 86.0 350.0 1.0‐86.0
Salbutamol 36 0.0 1.0 22.0 100.8 294.0 1.0‐100.8
Ezetimibe 31 0.0 0.0 24.0 62.0 242.0 0.0‐62.0
Amlodipine 124 0.0 4.5 35.5 103.3 341.0 4.5‐103.3
Allopurinol 41 0.0 3.0 39.0 180.0 319.0 3.0‐180.0
Lansoprazole 42 0.0 1.0 39.0 142.0 304.0 1.0‐142.0
Bisoprolol 60 0.0 0.0 45.0 93.3 350.0 0.0‐93.3
Candesartan 34 0.0 5.3 52.0 190.5 347.0 5.3‐190.5
Losartan 45 0.0 7.0 74.0 125.0 334.0 7.0‐125.0
The Steel test was performed for cases of the atorvastatin monotherapy group (n = 454) as the control group. IQR, interquartile range; MAEs, muscu-
loskeletal adverse events.
AKIMOTO ET AL. | 5 of 9
4 | DISCUSSION
4.1 | Onset timing of MAEs by statin type
The maximum number of cases of MAE onset was associated with
atorvastatin, followed by rosuvastatin and simvastatin, and the num-
ber of cases exceeded 400 for the three statins. The number of
MAE cases induced by pravastatin, lovastatin, fluvastatin, and
pitavastatin was small. In particular, only 16 cases were extracted for
pitavastatin. The onset timing for MAEs (median) induced by ator-
vastatin and rosuvastatin was respectively 24.5 and 30.0 days, which
was significantly shorter than those associated with simvastatin
(43.0 days). The onset timing for MAEs induced by pravastatin,
lovastatin, and fluvastatin were similar to simvastatin at generally
40 days.
The magnitude of HMG‐CoA reductase 50% inhibitory concen-
tration (IC50) for each statin was in the order of rosuvastatin < ator-
vastatin < simvastatin < fluvastatin < pravastatin.24 Atorvastatin or
rosuvastatin, which possesses a high HMG‐CoA reductase inhibitory
activity, is considered high‐intensity statin therapy that reduces LDL
cholesterol by more than 50%. The use of the other statins is con-
sidered either moderate or low‐intensity statin therapy.1 Hoffman et
al reported the following order for the relative risk of statin‐induced
MAEs: rosuvastatin > atorvastatin > simvastatin > pravastatin > lo-
vastatin.25 These indicate that the higher the HMG‐CoA reductase
inhibitory activity (or the lower the IC50) of a statin, the higher the
relative risk of MAEs tends to be. Previous study findings and the
results of the present study suggest that statins with a high HMG‐
CoA reductase inhibitory activity, such as atorvastatin and rosuvas-
tatin, not only increase the onset risk of MAEs, but also induce
MAEs within a short time.
We also considered the relationship between statin lipophilicity
and MAE onset timing. Rosuvastatin and pravastatin are known to
have very low lipophilicity than other statins (in descending order:
simvastatin > fluvastatin > atorvastatin > rosuvastatin > pravas-
tatin).24 Statin lipophilicity does not correlate with the relative risk
of statin‐induced MAEs nor the MAE onset timing for any statin.
Thus, it is unlikely that MAE risk and timing are affected by statin
lipophilicity.
Thus, our research finding that the onset timing of MAEs differs
with statin type is important for reducing the risk of side effects and
side effect prevention in a clinical setting. The onset timing for
MAEs in cases of pitavastatin use was extremely short. This might
be due to the very small number of cases (only 16) of pitavastatin
TABLE 3 Onset timing of MAEs induced by rosuvastatin and concomitant drugs
Concomitant drugs
No. of cases
(≥30 cases)
MAE onset (days)
IQRMinimum value First quartile Median Third quartile Maximum value
Ramipril 34 0.0 0.0 12.0 103.0 212.0 0.0‐103.0
Olmesartan 33 0.0 3.0 19.0 71.0 275.0 3.0‐71.0
Lansoprazole 30 0.0 0.3 25.0 147.8 357.0 0.3‐147.8
Clopidogrel 94 0.0 1.0 30.0 120.0 363.0 1.0‐120.0
Warfarin 46 0.0 1.3 30.0 69.0 317.0 1.3‐69.0
Aspirin 260 0.0 1.0 31.0 92.0 334.0 1.0‐92.0
Atenolol 61 0.0 0.0 31.0 78.0 362.0 0.0‐78.0
Levothyroxine 92 0.0 7.0 31.0 102.3 363.0 7.0‐102.3
Candesartan 31 0.0 0.5 32.0 75.5 282.0 0.5‐75.5
Lisinopril 79 0.0 1.5 34.0 115.5 363.0 1.5‐115.5
Omeprazole 90 0.0 2.3 34.5 125.5 314.0 2.3‐125.5
Metformin 64 0.0 0.0 36.0 105.0 334.0 0.0‐105.0
Acetaminophen 43 0.0 1.0 37.0 101.0 286.0 1.0‐101.0
Metoprolol 97 0.0 1.0 38.0 148.0 349.0 1.0‐148.0
Bisoprolol 35 0.0 10.5 40.0 113.0 334.0 10.5‐113.0
Valsartan 54 0.0 2.3 40.5 143.5 359.0 2.3‐143.5
Hydrochlorothiazide 84 0.0 2.8 45.5 116.0 334.0 2.8‐116.0
Amlodipine 89 0.0 5.0 47.0 116.0 363.0 5.0‐116.0
Esomeprazole 49 0.0 1.0 47.0 224.0 314.0 1.0‐224.0
Ezetimibe 44 0.0 0.8 50.0 117.5 258.0 0.8‐117.5
Furosemide 65 0.0 10.0 55.0 121.0 302.0 10.0‐121.0
Fluticasone 30 0.0 0.5 62.5 144.0 353.0 0.5‐144.0
The Steel test was performed for cases of the rosuvastatin monotherapy group (n = 413) as the control group. IQR, interquartile range; MAEs, muscu-
loskeletal adverse events.
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use. This could be attributable to the relatively recent approval of
pitavastatin (in 2009) compared to other statins and to its low pre-
scription rate.26,27 Thus, a more accurate onset timing for MAEs may
be determined in the future if spontaneous case reports continue to
accumulate in the FAERS.
4.2 | Effects of concomitant drugs on the onset
timing of MAEs
This study also investigated whether concomitant drugs used concur-
rently with statins impacted the onset timing of MAEs. The results
showed that concomitant drugs in all statin‐concomitant drug combina-
tions evaluated in this study did not affect the onset timing of MAEs.
Atorvastatin is mainly metabolised by CYP3A4 and partially by
CYP2C8.28,29 Similar to atorvastatin, 1,4‐dihydropyridine calcium
channel blockers such as amlodipine are metabolised by CYP3A4;
therefore, the MAE onset risk may increase because of DDI.30
However, the blood concentration is not greatly affected, and the
effect is not clinically significant.31 Similar to amlodipine, diltiazem
is metabolised by CYP3A4, and the MAE onset risk may
increase.30,32 Nevertheless, the concomitant use of atorvastatin
and diltiazem did not cause changes in the onset timing of MAEs
(Table 2).
Simvastatin is mostly metabolised by CYP3A4, while some of it
is metabolised by CYP2C8.33,34 It has been known that the concomi-
tant use of simvastatin and amlodipine increases the risk of myopa-
thy.35,36 In addition, the concomitant use of simvastatin and
cyclosporine is contraindicated as cyclosporine inhibits CYP3A4.37
However, these drugs did not cause changes in the onset timing of
MAEs.
Thus, it was clarified that even if the concomitant use of statins
and drugs that may cause DDI can change the MAE onset risk, it is
unlikely that the onset timing will be changed. The results also
showed that it is unlikely for other concomitant drugs, which are
thought to have no drug interaction with statins, to cause changes
in the onset timing of MAEs.
TABLE 4 Onset timing of MAEs induced by simvastatin and concomitant drugs
Concomitant drugs
No. of cases
(≥30 cases)
MAE onset (days)
IQRMinimum value First quartile Median Third quartile Maximum value
Fluticasone 34 0.0 0.0 12.5 73.8 250.0 0.0‐73.8
Amlodipine 93 0.0 1.0 20.0 91.0 334.0 1.0‐91.0
Isosorbide Mononitrate 37 0.0 12.0 26.0 69.0 290.0 12.0‐69.0
Atenolol 74 0.0 0.8 26.5 90.5 313.0 0.8‐90.5
Diltiazem 56 0.0 5.5 26.5 73.5 335.0 5.5‐73.5
Losartan 42 0.0 0.5 27.5 109.3 351.0 0.5‐109.3
Clopidogrel 115 0.0 5.5 29.0 91.0 362.0 5.5‐91.0
Ramipril 68 0.0 10.3 29.0 77.0 301.0 10.3‐77.0
Aspirin 249 0.0 3.0 30.0 99.0 364.0 3.0‐99.0
Furosemide 107 0.0 4.0 30.0 76.0 351.0 4.0‐76.0
Metoprolol 102 0.0 5.3 30.0 117.3 364.0 5.3‐117.3
Omeprazole 110 0.0 4.0 30.5 73.0 333.0 4.0‐73.0
Salbutamol 46 0.0 2.0 30.5 98.0 325.0 2.0‐98.0
Levothyroxine 75 0.0 5.0 31.0 127.5 352.0 5.0‐127.5
Pantoprazole 35 0.0 5.5 31.0 185.0 301.0 5.5‐185.0
Hydrochlorothiazide 68 0.0 0.0 33.0 153.5 338.0 0.0‐153.5
Metformin 84 0.0 9.0 33.5 130.8 364.0 9.0‐130.8
Allopurinol 47 0.0 16.5 34.0 108.0 263.0 16.5‐108.0
Lisinopril 91 0.0 4.0 34.0 121.0 335.0 4.0‐121.0
Cyclosporine 38 0.0 14.5 34.5 94.8 352.0 14.5‐94.8
Lansoprazole 37 0.0 12.0 37.0 202.0 364.0 12.0‐202.0
Warfarin 43 0.0 12.0 41.0 165.5 303.0 12.0‐165.5
Bisoprolol 56 0.0 13.0 43.5 172.5 352.0 13.0‐172.5
Gemfibrozil 59 0.0 30.5 45.0 114.5 351.0 30.5‐114.5
Ezetimibe 30 0.0 19.3 52.0 95.8 335.0 19.3‐95.8
Acetaminophen 71 0.0 6.0 61.0 142.0 333.0 6.0‐142.0
Nitroglycerin 42 0.0 23.0 64.5 197.3 351.0 23.0‐197.3
The Steel test was performed for cases of the simvastatin monotherapy group (n = 409) as the control group. IQR, interquartile range; MAEs, muscu-
loskeletal adverse events.
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This study has certain limitations. (1) This study did not include cases
reported before 2004, because only data from the year 2004 was
available for download from FAERS. Therefore, cases of statin use
before 2001, which had been analysed by Chang et al, could not be
evaluated in this study, and the number of cases reported for some
statins was insufficient. (2) This study considered only four types of
adverse events as MAEs for analysis: rhabdomyolysis, myoglobinuria,
myalgia, and blood creatine phosphokinase increased. The latter two
are common side effects of statins; however, this does not mean that
statins are necessarily the cause of these adverse events when they
do occur. Moreover, the magnitude of creatine phosphokinase
increase (ie, in terms of laboratory test values) was not reported in the
records of cases receiving statins in the FAERS database. Accordingly,
our data cannot be interpreted to conclusively prove that any of the
four phenotypes defined here were caused by statins in the analysed
cases with concomitant nonstatin drugs. (3) Statin dosage is related to
the intensity of LDL cholesterol‐lowering effect. For example, a daily
dose of rosuvastatin 20 mg is considered a high‐intensity statin ther-
apy, while a daily dose of rosuvastatin 10 mg is a moderate‐intensity
statin therapy.1 Therefore, if the intensity of statin therapy is related
to the time‐to‐onset for MAEs, the dosage must be taken into consid-
eration. However, in cases reported to FAERS, data regarding adminis-
tration and dosage are often missing; thus, the statin dosage of each
case could not be taken into consideration. Hence, the changes in
onset timing of MAEs dependent on statin dosage could not be evalu-
ated in this study.
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